Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.62 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.62 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
| ▸ | EDNRB | P24530 | 2/20 | 0.42 |
| ▸ | EDNRA | P25101 | 2/20 | 0.42 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620013 | 0.92 | HSD11B1 (0.62) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3618471 | 0.88 | HSD11B1 (0.58) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL27534009 | 0.87 | HSD11B1 (0.69) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL3616536 | 0.86 | HSD11B1 (0.68) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3602689 | 0.85 | HSD11B1 (0.66) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL5911680 | 0.85 | HSD11B1 (0.69) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3619881 | 0.84 | HSD11B1 (0.65) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3614770 | 0.84 | HSD11B1 (0.65) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3612077 | 0.84 | HSD11B1 (0.68) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL5911760 | 0.83 | HSD11B1 (0.67) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | claimed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | claimed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | claimed |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | disclosed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | disclosed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885 |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.